Scientific Publications & Presentations

These scientific publications and presentations are provided for educational purposes only. They may discuss or mention DBV Technologies’ products under clinical investigation, which have not been approved for marketing by any health or regulatory authority in any country.

Key Publications

Pongracic JA, Gagnon R, et al. Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results. J Allergy Clin Immunol Pract. 2021. Nov 27;S2213-2198(21)01295-2. doi: 10.1016/j.jaip.2021.11.017.

Bégin P, Bird JA, et al. Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy. Allergy. 2021. Dec;76(12):3835-3838. doi: 10.1111/all.15083.

Remington BC, Koppelman SJ, et al. Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: a novel approach to assessing relevance. Allergy. 2021. Oct;76(10):3223-3226. doi: 10.1111/all.14973.

Remington BC, Campbell DE, et al. Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results: Relevance for exposure through restaurant meals. Annals of Allergy, Asthma & Immunology. 2021. Feb126(2):208-209. doi: 10.1016/j.anai.2020.11.015.

Brown-Whitehorn TF, de Blay F, et al. Sustained Unresponsiveness to Peanut After Long-term Peanut Epicutaneous Immunotherapy. The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):524-526. doi: 10.1016/j.jaip.2020.08.017.

DunnGalvin A, Fleischer DM, et al. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies. The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):216-224.e1. doi: 10.1016/j.jaip.2020.08.015.

Fleischer DM, Shreffler WG, et al. Long-Term, Open-Label Extension Study of the Efficacy and Safety of Epicutaneous Immunotherapy For Peanut Allergy in Children: PEOPLE 3-Year Results. The Journal of Allergy and Clinical Immunology. 2020. doi:10.1016/j.jaci.2020.06.028.

Fleischer DM, Chinthrajah S, et al. An Evaluation of Factors Influencing Response to Epicutaneous Immunotherapy For Peanut Allergy in the PEPITES Trial. Allergy & Asthma Proceedings. 2020;41:1-10. doi:10.2500/aap.2020.41.200047. PMID: 32539908.

Fleischer DM, Spergel JM, et al. Evaluation of Daily Patch Application Duration For Epicutaneous Immunotherapy For Peanut Allergy. Allergy & Asthma Proceedings. 2020;41:278-284. doi:10.2500/aap.2020.41.200045. PMID: 32517847.

Greenhawt M, Kim EH, et al. Improvements in Eliciting Dose Across Baseline Sensitivities Following 12 Months of Epicutaneous Immunotherapy (EPIT) in Peanut-Allergic Children Aged 4 to 11 Years. The Journal of Allergy and Clinical Immunology: In Practice. 2020;S2213-2198(20)30526-2. doi:10.1016/j.jaip.2020.05.030. PMID: 32502548.

Fleischer DM, Greenhawt M, et al. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. 2019;321:946-955. doi:10.1001/jama.2019.1113. PMID: 30794314.

Sampson HA, Shreffler WG, et al. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. JAMA. 2017;318:1798-1809. doi:10.1001/jama.2017.16591. PMID: 29136445.

Recent Presentations

These abstracts were accepted for presentation at medical congresses and have not been subjected to full peer review.

American College of Allergy, Asthma & Immunology (ACAAI) 2021 Annual Scientific Meeting:

Oral Presentations:

  • REALISE (Real-life Use and Safety of EPIT) Study: 3 Year Results in Peanut-allergic Children – Terri F. Brown-Whitehorn, MD [Abstract D030]

Poster Presentations:

  • REALISE (Real-life Use and Safety of EPIT) Study: Health-related Quality of Life Changes During Treatment – Dareen Siri, MD [Abstract P116]

American Academy of Allergy, Asthma & Immunology (AAAAI) 2021 Annual Meeting:

Poster Presentations:

  • Reduction in severity following 12 months of epicutaneous immunotherapy for peanut allergy (Abstract 342)
  • Modulation of mast cells by epicutaneous immunotherapy (EPIT) to cashew allergy (Abstract L15)